Key strengths include a differentiated and growing hepatitis B franchise, a high‑margin business model typical of successful vaccines, and a proprietary adjuvant platform with broad applicability. The balance sheet and liquidity are meaningfully stronger than a few years ago, providing resilience and flexibility. Dynavax has also shown it can generate positive free cash flow in normal conditions, and its technology and products are compelling enough to attract a premium acquisition agreement from a global vaccine leader, which validates the strategic importance of its platform.

The most notable risks stem from concentration and volatility. The company relies heavily on a limited number of products and on the continued success of HEPLISAV‑B, while historical results show that revenue and earnings can swing sharply when temporary contracts end or demand changes. Free cash flow has been trending down from pandemic highs, even as share repurchases and R&D commitments continue, which could tighten financial flexibility over time. Scientifically, the pipeline faces the usual clinical, regulatory, and competitive uncertainties; commercially, large incumbents and new technologies could challenge both HEPLISAV‑B and future products. Integration into Sanofi adds another layer of uncertainty about future strategy, resource allocation, and the pace at which Dynavax’s programs are advanced.

Dynavax appears to be transitioning from a small, opportunistic biotech that benefited from COVID‑era demand into a more stable vaccine platform that will likely operate within Sanofi’s global infrastructure. Near‑term fundamentals are likely to reflect a more modest, core revenue base centered on HEPLISAV‑B and ongoing adjuvant deals, with profitability sensitive to how tightly operating costs are managed. Over the medium to long term, the outlook depends heavily on the success of key pipeline assets—especially the shingles candidate—and on how effectively Sanofi leverages CpG 1018 across its wider vaccine portfolio. The company’s technology and balance sheet position it reasonably well, but future performance will hinge on execution, clinical outcomes, and strategic priorities under its new owner.